Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro‐Fibrotic Signaling

BACKGROUND: Experimental uremic cardiomyopathy causes cardiac fibrosis and is causally related to the increased circulating levels of the cardiotonic steroid, marinobufagenin (MBG), which signals through Na/K‐ATPase. Rapamycin is an inhibitor of the serine/threonine kinase mammalian target of rapamy...

Descripción completa

Detalles Bibliográficos
Autores principales: Haller, Steven T., Yan, Yanling, Drummond, Christopher A., Xie, Joe, Tian, Jiang, Kennedy, David J., Shilova, Victoria Y., Xie, Zijian, Liu, Jiang, Cooper, Christopher J., Malhotra, Deepak, Shapiro, Joseph I., Fedorova, Olga V., Bagrov, Alexei Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121507/
https://www.ncbi.nlm.nih.gov/pubmed/27694325
http://dx.doi.org/10.1161/JAHA.116.004106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121507/
https://www.ncbi.nlm.nih.gov/pubmed/27694325
http://dx.doi.org/10.1161/JAHA.116.004106

Ejemplares similares